005250.KS
Green Cross Holdings Corporation [005250.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
005250.KS Stock Summary
Top 10 Correlated ETFs
005250.KS
Top 10 Correlated Stocks
005250.KS
In the News
005250.KS Financial details
Company Rating
Buy
Market Cap
651.1B
Income
2.44B
Revenue
2034.74B
Book val./share
22389.33
Cash/share
3737.22
Dividend
300
Dividend %
2.15%
Employees
160
Optionable
No
Shortable
Yes
Earnings
13 Nov 2023
P/E
253.55
Forward P/E
-
PEG
-25.81
P/S
0.31
P/B
0.62
P/C
3.73
P/FCF
-3.07
Quick Ratio
0.51
Current Ratio
0.92
Debt / Equity
1.1
LT Debt / Equity
0.25
-
-
EPS (TTM)
49.79
EPS next Y
-
EPS next Q
-
EPS this Y
-53.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
26.42%
Revenue last 5Y
6.08%
Revenue Q/Q
22.37%
EPS Q/Q
-72.1%
-
-
-
-
SMA20
3.49%
SMA50
4.8%
SMA100
-9.85%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
31%
Oper. Margin
-
Profit Margin
-
Payout
1263%
Shs Outstand
44.93M
Shs Float
24.29M
-
-
-
-
Target Price
-
52W Range
12920.0-19450.0
52W High
-28.33%
52W Low
+7.89%
RSI
43
Rel Volume
0.46
Avg Volume
70.96K
Volume
32.34K
Perf Week
-7.07%
Perf Month
1.23%
Perf Quarter
-13.31%
Perf Half Y
-8.71%
-
-
-
-
Beta
0.934507
-
-
Volatility
286.26%, 516.08%
Prev Close
0%
Price
13940
Change
0.72%
005250.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 34.03K | 33.93K | 38.15K | 40.69K | 46.28K | |
| Net income per share | 406 | -678.25 | 1.56K | 2.82K | 1.31K | |
| Operating cash flow per share | 827.63 | 170.26 | 846.15 | 2.29K | 2.16K | |
| Free cash flow per share | -2.43K | -3.5K | -2.16K | -841.62 | -668.17 | |
| Cash per share | 5.97K | 4.94K | 11.31K | 8.81K | 5.34K | |
| Book value per share | 17.68K | 18.09K | 20.4K | 22.67K | 23.09K | |
| Tangible book value per share | 29.03K | 30.41K | 30.16K | 30.46K | 28.95K | |
| Share holders equity per share | 17.68K | 18.09K | 20.4K | 22.67K | 23.09K | |
| Interest debt per share | 17.81K | 19.45K | 21.78K | 21.13K | 22.45K | |
| Market cap | 1109.81B | 999.79B | 1870.51B | 1227.97B | 745.91B | |
| Enterprise value | 1651.48B | 1678.71B | 2380.43B | 1820.39B | 1509.6B | |
| P/E ratio | 60.1 | -32.81 | 26.58 | 9.62 | 12.66 | |
| Price to sales ratio | 0.72 | 0.66 | 1.09 | 0.67 | 0.36 | |
| POCF ratio | 29.48 | 130.68 | 49.05 | 11.83 | 7.68 | |
| PFCF ratio | -10.06 | -6.35 | -19.17 | -32.26 | -24.84 | |
| P/B Ratio | 1.38 | 1.23 | 2.03 | 1.2 | 0.72 | |
| PTB ratio | 1.38 | 1.23 | 2.03 | 1.2 | 0.72 | |
| EV to sales | 1.07 | 1.1 | 1.38 | 0.99 | 0.73 | |
| Enterprise value over EBITDA | 17.18 | 18.57 | 16.26 | 7.42 | 9.25 | |
| EV to operating cash flow | 43.87 | 219.43 | 62.42 | 17.54 | 15.54 | |
| EV to free cash flow | -14.96 | -10.67 | -24.4 | -47.82 | -50.28 | |
| Earnings yield | 0.02 | -0.03 | 0.04 | 0.1 | 0.08 | |
| Free cash flow yield | -0.1 | -0.16 | -0.05 | -0.03 | -0.04 | |
| Debt to equity | 0.99 | 1.05 | 1.04 | 0.9 | 0.94 | |
| Debt to assets | 0.3 | 0.31 | 0.3 | 0.27 | 0.27 | |
| Net debt to EBITDA | 5.64 | 7.51 | 3.48 | 2.42 | 4.68 | |
| Current ratio | 1.73 | 1.66 | 1.39 | 1.54 | 1.2 | |
| Interest coverage | 2.81 | 1.65 | 2.91 | 6.64 | 1.95 | |
| Income quality | 1.94 | -0.25 | 0.21 | 0.81 | 1.65 | |
| Dividend Yield | 0.02 | 0.02 | 0.01 | 0.03 | 0.04 | |
| Payout ratio | 1.2 | -0.6 | 0.3 | 0.25 | 0.53 | |
| Sales general and administrative to revenue | 0.04 | 0.03 | 0.02 | 0.02 | 0.03 | |
| Research and developement to revenue | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.1 | 0.15 | 0.19 | |
| Capex to operating cash flow | -3.93 | -21.57 | -3.56 | -1.37 | -1.31 | |
| Capex to revenue | -0.1 | -0.11 | -0.08 | -0.08 | -0.06 | |
| Capex to depreciation | -3.13 | -2.9 | -2.57 | -2.27 | -1.62 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 12.71K | 16.61K | 26.77K | 37.94K | 26.1K | |
| ROIC | 0.01 | 0.04 | 0.02 | 0.07 | 0.07 | |
| Return on tangible assets | 0.01 | -0.01 | 0.02 | 0.04 | 0.02 | |
| Graham Net | -7.85K | -10.74K | -9.13K | -12.06K | -16.62K | |
| Working capital | 482.8B | 447.31B | 433.03B | 498.95B | 209.62B | |
| Tangible asset value | 1320.53B | 1366.64B | 1359.56B | 1377.48B | 1300.89B | |
| Net current asset value | -30.89B | -143.62B | -31.9B | -161.24B | -363.04B | |
| Invested capital | 0.99 | 1.05 | 1.04 | 0.9 | 0.94 | |
| Average receivables | 432.31B | 444.79B | 491.83B | 526.95B | 516.34B | |
| Average payables | 190.87B | 160.13B | 155.93B | 155.41B | 154.12B | |
| Average inventory | 463.99B | 442.64B | 471.46B | 498.07B | 506.04B | |
| Days sales outstanding | 104.14 | 107.22 | 113.73 | 102.76 | 90.31 | |
| Days payables outstanding | 54.4 | 50.01 | 49.68 | 44.87 | 42.09 | |
| Days of inventory on hand | 137.9 | 151.26 | 150.15 | 152.68 | 133.47 | |
| Receivables turnover | 3.51 | 3.4 | 3.21 | 3.55 | 4.04 | |
| Payables turnover | 6.71 | 7.3 | 7.35 | 8.14 | 8.67 | |
| Inventory turnover | 2.65 | 2.41 | 2.43 | 2.39 | 2.73 | |
| ROE | 0.02 | -0.04 | 0.08 | 0.12 | 0.06 | |
| Capex per share | -3.25K | -3.67K | -3.01K | -3.14K | -2.83K |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 11.51K | 12.32K | 11.27K | 9.78K | 12.07K | |
| Net income per share | -66.26 | 528.84 | 607.38 | -849.43 | -237 | |
| Operating cash flow per share | 465.77 | -756.61 | 2.62K | -1.81K | -1.33K | |
| Free cash flow per share | -191.12 | -1.48K | 1.66K | -2.7K | -2.05K | |
| Cash per share | 7.52K | 6.43K | 5.34K | 4.11K | 3.74K | |
| Book value per share | 22.46K | 22.62K | 23.09K | 22.47K | 22.39K | |
| Tangible book value per share | 28.49K | 29.09K | 28.95K | 27.51K | 27.27K | |
| Share holders equity per share | 22.46K | 22.62K | 23.09K | 22.47K | 22.39K | |
| Interest debt per share | 22.52K | 23.18K | 21.88K | 26.35K | 25K | |
| Market cap | 880.71B | 732.43B | 745.91B | 691.19B | 633.46B | |
| Enterprise value | 1603.48B | 1521.76B | 1509.6B | 1713.45B | 1582.44B | |
| P/E ratio | -73.95 | 7.71 | 6.83 | -4.54 | -15.03 | |
| Price to sales ratio | 1.7 | 1.32 | 1.47 | 1.58 | 1.18 | |
| POCF ratio | 42.08 | -21.54 | 6.34 | -8.52 | -10.71 | |
| PFCF ratio | -102.55 | -11.05 | 9.98 | -5.71 | -6.95 | |
| P/B Ratio | 0.87 | 0.72 | 0.72 | 0.69 | 0.64 | |
| PTB ratio | 0.87 | 0.72 | 0.72 | 0.69 | 0.64 | |
| EV to sales | 3.1 | 2.75 | 2.98 | 3.91 | 2.95 | |
| Enterprise value over EBITDA | 52.12 | 22.88 | 3.54K | -188.45 | 9.43 | |
| EV to operating cash flow | 76.62 | -44.76 | 12.84 | -21.11 | -26.76 | |
| EV to free cash flow | -186.71 | -22.95 | 20.2 | -14.16 | -17.35 | |
| Earnings yield | 0 | 0.03 | 0.04 | -0.06 | -0.02 | |
| Free cash flow yield | -0.01 | -0.09 | 0.1 | -0.18 | -0.14 | |
| Debt to equity | 0.99 | 1.01 | 0.94 | 1.16 | 1.1 | |
| Debt to assets | 0.28 | 0.28 | 0.27 | 0.33 | 0.3 | |
| Net debt to EBITDA | 23.49 | 11.87 | 1.79K | -112.43 | 5.66 | |
| Current ratio | 1.36 | 1.34 | 1.2 | 1.13 | 0.92 | |
| Interest coverage | 1.14 | 4.44 | -2.06 | -2.43 | 0.56 | |
| Income quality | -7.03 | -1.43 | 4.31 | 2.13 | 4.61 | |
| Dividend Yield | 0.03 | 0 | 0 | 0 | 0.05 | |
| Payout ratio | -10.08 | 0.04 | 0 | 0 | -2.84 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.04 | 0.03 | 0.3 | |
| Research and developement to revenue | 0.1 | 0.09 | 0.12 | 0.11 | 0.09 | |
| Intangibles to total assets | 0.18 | 0.18 | 0.19 | 0.19 | 0.19 | |
| Capex to operating cash flow | -1.41 | 0.95 | -0.36 | 0.49 | 0.54 | |
| Capex to revenue | -0.06 | -0.06 | -0.08 | -0.09 | -0.06 | |
| Capex to depreciation | -1.64 | -1.65 | -1.88 | -1.77 | -1.33 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.79K | 16.41K | 17.77K | 20.72K | 10.93K | |
| ROIC | 0.01 | 0.01 | 0.01 | -0.01 | 0.01 | |
| Return on tangible assets | 0 | 0.01 | 0.01 | -0.01 | 0 | |
| Graham Net | -14.14K | -14.96K | -16.62K | -18.6K | -19.63K | |
| Working capital | 360.63B | 370.61B | 209.62B | 139.69B | -103.41B | |
| Tangible asset value | 1280.3B | 1307.04B | 1300.89B | 1232.96B | 1212.08B | |
| Net current asset value | -254.06B | -255.92B | -363.04B | -431.67B | -452.02B | |
| Invested capital | 0.99 | 1.01 | 0.94 | 1.16 | 1.1 | |
| Average receivables | 536.49B | 590.63B | 582.63B | 508.01B | 516.94B | |
| Average payables | 147.16B | 149.05B | 158.64B | 165.75B | 185.06B | |
| Average inventory | 496.36B | 499.41B | 504.75B | 527.13B | 560.25B | |
| Days sales outstanding | 92.33 | 105.78 | 91.44 | 102.98 | 89.34 | |
| Days payables outstanding | 36.55 | 39.72 | 40.57 | 49.34 | 48.32 | |
| Days of inventory on hand | 129 | 126.8 | 128.66 | 157.32 | 139.52 | |
| Receivables turnover | 0.97 | 0.85 | 0.98 | 0.87 | 1.01 | |
| Payables turnover | 2.46 | 2.27 | 2.22 | 1.82 | 1.86 | |
| Inventory turnover | 0.7 | 0.71 | 0.7 | 0.57 | 0.65 | |
| ROE | 0 | 0.02 | 0.03 | -0.04 | -0.01 | |
| Capex per share | -656.89 | -718.94 | -954.07 | -888.99 | -721.32 |
005250.KS Frequently Asked Questions
What is Green Cross Holdings Corporation stock symbol ?
Green Cross Holdings Corporation is a KR stock and trading under the symbol 005250.KS
What is Green Cross Holdings Corporation stock quote today ?
Green Cross Holdings Corporation stock price is $13940 today.
Is Green Cross Holdings Corporation stock public?
Yes, Green Cross Holdings Corporation is a publicly traded company.
Company Profile
- Volume Average 70.96K
- Market Capitalization 651.1B
- Employee 160
- CEO Mr. Il-Sup Huh Ph.D.
- Headquarters Yongin-Si,KR
- IPO Date 2000-01-04
-
Website
https://www.greencross.com 
Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.
